ArticleBMC cancer2022

Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.

Heng Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.